OTCMKTS:BNVIQ - Bionovo Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started $0.0003 0.00 (0.00 %) (As of 04/11/2016)Previous Close$0.0003Today's Range$0.0003 - $0.000352-Week Range$0.0003 - $0.0027VolumeN/AAverage Volume96,632 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bionovo, Inc. is a drug discovery and development company, which focuses on women's health and development of drugs for the treatment of cancer. The Company's drug candidates include Menerba, Seala, Bezielle, BN107 and BN108. Its Menerba is a selective estrogen receptor beta agonist, which reduces the frequency and severity of menopausal hot flashes. The Company has completed a randomized, double-blind, placebo-controlled Phase II clinical trial of Menerba. Bezielle is an orally delivered anti-cancer agent. The Company is engaged in an open label, multi-center Phase I/II trial of Bezielle for the treatment of advanced metastatic breast cancer. The Company's Seala is a selective estrogen receptor beta agonist, which acts as an intra-vaginal suppository. The Company's anti-cancer agents include BN107 and BN108, which are used for the treatment of advanced breast cancer. BN107 and BN108 are in pre-clinical development stage. Receive BNVIQ News and Ratings via Email Sign-up to receive the latest news and ratings for BNVIQ and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry N/A Sub-IndustryN/A SectorN/A Current SymbolOTCMKTS:BNVIQ Previous SymbolNASDAQ:BNVI CUSIPN/A CIKN/A Webbionovo.com Phone+1-510-6012000Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Bionovo (OTCMKTS:BNVIQ) Frequently Asked Questions What is Bionovo's stock symbol? Bionovo trades on the OTCMKTS under the ticker symbol "BNVIQ." Has Bionovo been receiving favorable news coverage? Press coverage about BNVIQ stock has trended somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Bionovo earned a news sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the healthcare company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. What is Bionovo's stock price today? One share of BNVIQ stock can currently be purchased for approximately $0.0003. What is Bionovo's official website? The official website for Bionovo is http://bionovo.com/. How can I contact Bionovo? Bionovo's mailing address is 5858 Horton St Ste 400, EMERYVILLE, CA 94608-2046, United States. The healthcare company can be reached via phone at +1-510-6012000. MarketBeat Community Rating for Bionovo (OTCMKTS BNVIQ)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 41 (Vote Outperform)Underperform Votes: 28 (Vote Underperform)Total Votes: 69MarketBeat's community ratings are surveys of what our community members think about Bionovo and other stocks. Vote "Outperform" if you believe BNVIQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNVIQ will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Closed-End Mutual Funds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.